Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has gained more than 15% over the past month, mainly driven by the stock’s inclusion in the Russell 3000 index and strong Q1 2026 earnings. Wall Street expects more than 21% upside over the next 12-months making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts.

​During the fiscal Q1 2026 earnings, the company posted $21.1 million in revenue, surpassing the expectations of $9.78 million by a huge margin. Revenue for the quarter grew 1,523% year-over-year, driven by $20 million in development milestones from the Novo Nordisk licensing agreement for the LX9851 obesity program.

Moreover, liquidity also strengthened with a new $100 million loan facility from Hercules Capital, with an initial $55 million funded to support operations for at least the next 12 months. Management also highlighted that the progress for the SONATA-HCM Phase 3 trial remains strong and that the company plans to resubmit the ZYNQUISTA New Drug Application for type 1 diabetes by mid-2026.

​Last month, on May 11, Citi raised the price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $3.10 from $2.30 and maintained a Buy rating on the shares.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on developing and commercializing therapies for human disease.

READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now. 

Disclosure: None. Follow Insider Monkey on Google News.